Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer

BACKGROUND: Trabectedin, in addition to its antiproliferative effect, can modify the tumour microenvironment and this could be synergistic with bevacizumab. The efficacy and safety of trabectedin and bevacizumab ± carboplatin have never been investigated. METHODS: In this phase 2 study, women progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Nicoletta, Zaccarelli, Eleonora, Baldoni, Alessandra, Frezzini, Simona, Scambia, Giovanni, Palluzzi, Eleonora, Tognon, Germana, Lissoni, Andrea A., Rubino, Daniela, Ferrero, Annamaria, Farina, Gabriella, Negri, Emanuele, Pesenti Gritti, Angela, Galli, Francesca, Biagioli, Elena, Rulli, Eliana, Poli, Davide, Gerardi, Chiara, Torri, Valter, Fossati, Roldano, D‘Incalci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888836/
https://www.ncbi.nlm.nih.gov/pubmed/31537908
http://dx.doi.org/10.1038/s41416-019-0584-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888836/
https://www.ncbi.nlm.nih.gov/pubmed/31537908
http://dx.doi.org/10.1038/s41416-019-0584-5

Ejemplares similares